预约演示
更新于：2026-09-11
Ivabradine Hydrochloride
盐酸伊伐布雷定
更新于：2026-09-11
概要
基本信息
药物类型 小分子化药 |
别名 CORALAN、Coraxan、IVABRADINE + [18] |
作用方式 阻滞剂 |
作用机制 HCN channels阻滞剂(超极化激活环核苷酸门控阳离子通道阻滞剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H37ClN2O5 |
InChIKeyHLUKNZUABFFNQS-ZMBIFBSDSA-N |
CAS号148849-67-6 |
关联
226
项与 盐酸伊伐布雷定 相关的临床试验NCT07717710
Heart Rate Reduction Via Oral Ivabradine During Exercise in Healthy Adults to Understand Heart Rate/Work-rate Relations: A Pilot Dose-selection Study
NCT07797946
Comparison of Two Preoperative Ivabradin Regimens for Hemodynamic Stability During Functional Endoscopic Sinus Surgery
CTRI/2025/12/099041
Heart rate control with Ivabradine vs Esmolol for RefrActoRy taCHYcardia in Septic Shock â?? A randomized controlled trial. - HIERARCHY-SS
100 项与 盐酸伊伐布雷定 相关的临床结果
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的转化医学
登录后查看更多信息
100 项与 盐酸伊伐布雷定 相关的专利（医药）
登录后查看更多信息
1,876
项与 盐酸伊伐布雷定 相关的文献（医药）2026-09-01EXPERIMENTAL EYE RESEARCH
Retinal ON- and OFF-pathway dysfunction due to HCN channel inhibition evaluated using dark and light adapted flicker electroretinograms in rats
Article
作者: Umeya, Naohisa ; Usui, Toru ; Miyawaki, Izuru
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitors that induce visual abnormalities such as phosphenes in humans are believed to disrupt the feedback mechanisms of retinal photoreceptor cells and cause dysfunction of the ON and OFF pathways in the retina. However, this hypothesis is based mainly on studies using HCN channel-knockout mice. In this study, we evaluated whether the retinal ON and OFF pathway defects could be detected in animals treated with HCN channel inhibitors by dark-adapted and light-adapted flicker electroretinography (ERG). Ivabradine, an HCN channel inhibitor, was administered subcutaneously to Long-Evans rats at 4-40 mg/kg as a single dose, and dark- and light-adapted flicker ERGs were measured at frequencies ranging from 1 to 30 Hz. In dark-adapted flicker ERGs, waveforms including rod photoreceptor components in the low frequency range and rod ON pathway and cone ON and OFF pathway components in the intermediate- and high-frequency range were changed, and the amplitude of the waveforms were attenuated. These inhibitions of cone ON and OFF pathways were considered, based on the results of the light-adapted flicker ERGs, to have been influenced by interference with rod-driven signals via gap junctions. This study is the first report to demonstrate inhibition of ON and OFF pathway signaling in animals treated with an HCN channel inhibitor. Our findings also suggest that dark- and light-adapted flicker ERGs across a range of frequencies may be a useful tool for detecting retinal dysfunction caused by compounds inducing visual abnormalities.
2026-08-01ANNALS OF PHARMACOTHERAPY
Ivabradine Use for Arrhythmias in Children
Article
作者: Stephens, Katy S. ; Miller, Jamie L. ; Behere, Shashank ; Foote, David ; Le, Monica ; Johnson, Peter N.
Background::
Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that has an off-label indication for arrhythmias in pediatric patients.
Objectives::
The primary objective was identification of the line of therapy and type of arrhythmia for which ivabradine was initiated. The secondary objective was to evaluate the initial and peak ivabradine doses, tolerance in partially fed patients (i.e., patients not receiving full feeds at the time of ivabradine initiation), number of patients continued home on ivabradine, concomitant drug interactions with a class C, D, or X classification, and adverse effects.
Methods::
A retrospective study of hospitalized patients <18 years of age receiving ivabradine for arrhythmias between January 1, 2021 and November 30, 2023. Data variables included demographics, ivabradine dosing regimens, concomitant anti-arrhythmic medications, percentage of ivabradine course while receiving full enteral feeds, concomitant medications with drug-drug interactions, and adverse effects (bradycardia [defined as <100 beats/min in neonates and <50 beats/min in infants and children], atrial fibrillation, vision changes, and emesis attributed to ivabradine).
Results::
Seventeen patients were included. The most frequent arrhythmia indication was atrial tachycardia and ivabradine was most frequently used as a third-line anti-arrhythmic. Ten (58.8%) received ivabradine despite not being on full enteral feeds. The median initial and peak ivabradine doses were 0.05 mg/kg/dose and 0.07 mg/kg/dose, respectively, and it was most frequently administered every 12 hours. Only 1 patient required a dose decrease for a noted adverse effect. Most patients (94.1%) had a Class C drug-drug interaction, and 3 had a Class X interaction. Ten (58.8%) were discharged home on ivabradine.
Conclusions and relevance::
Ivabradine was safe and effective as additive therapy for the treatment of pediatric arrhythmias. Larger studies of ivabradine use in pediatric arrhythmias are needed.
2026-08-01JACC. Case reports
Ivabradine in a Neonate With Severe Hypertrophic Cardiomyopathy
Article
作者: Guerrier, Karine ; Martinez, Hugo R ; Baxter, Genevieve ; Ryan, Kaitlin ; Karikari, Yaa S
BACKGROUND:
Hypertrophic cardiomyopathy (HCM) affects approximately 20% of patients with Noonan syndrome and contributes significantly to mortality, particularly in neonates with severe HCM and left ventricular outflow tract obstruction, where controlling heart rate (HR) and maintaining systemic vascular resistance can be challenging.
CASE SUMMARY:
A full-term neonate with an Raf-1 proto-oncogene, serine/threonine kinase mutation and severe HCM developed diastolic heart failure requiring high-dose esmolol for rate control and phenylephrine for systemic vascular resistance support. After inadequate HR response and associated vasodilation due to esmolol, off-label ivabradine was started at 20 days of life, achieving HR control within 48 hours and allowing weaning of vasoactive agents and respiratory support.
DISCUSSION:
Standard therapies-β-blockers, nondihydropyridine calcium channel blockers, and sodium-channel blockers-can worsen left ventricular outflow tract obstruction. Ivabradine selectively inhibits the I(f) current via hyperpolarization-activated cyclic nucleotide-gated channel 4 in sinoatrial tissue, providing HR reduction without compromising contractility or hemodynamics.
TAKE-HOME MESSAGE:
Ivabradine provides durable HR control without negative inotropy or hypotension, supporting its use in symptomatic pediatric HCM.
153
项与 盐酸伊伐布雷定 相关的新闻（医药）2026-08-29
2026-08-20
100 项与 盐酸伊伐布雷定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 射血分数降低的慢性心力衰竭 | 澳大利亚 | 2026-07-16 | |
| 心绞痛 | 中国 | 2015-04-29 | |
| 心脏衰竭 | 美国 | 2015-04-15 | |
| 稳定型心绞痛 | 欧盟 | 2005-10-25 | |
| 稳定型心绞痛 | 冰岛 | 2005-10-25 | |
| 稳定型心绞痛 | 列支敦士登 | 2005-10-25 | |
| 稳定型心绞痛 | 挪威 | 2005-10-25 | |
| 慢性心力衰竭 | 欧盟 | 2005-10-25 | |
| 慢性心力衰竭 | 冰岛 | 2005-10-25 | |
| 慢性心力衰竭 | 列支敦士登 | 2005-10-25 | |
| 慢性心力衰竭 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 体位性心动过速综合征 | 临床3期 | 美国 | 2018-02-06 | |
| 动脉粥样硬化斑块 | 临床3期 | 比利时 | 2013-04-11 | |
| 冠心病 | 临床3期 | 英国 | 2004-12-01 | |
| 左心室收缩功能障碍 | 临床3期 | 英国 | 2004-12-01 | |
| 神经痛 | 临床2期 | 英国 | 2014-04-14 | |
| 内皮功能障碍 | 临床2期 | 英国 | 2013-07-22 | |
| 舒张期心力衰竭 | 临床2期 | 奥地利 | 2013-07-17 | |
| 扩张型心肌病 | 临床2期 | 比利时 | 2011-10-20 | |
| 缺血 | 临床2期 | 意大利 | 2011-09-26 | |
| 心肌顿抑 | 临床2期 | 意大利 | 2011-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 381 | Ivabradine Placebo + Usual Care+Ivabradine + Usual Care (Ivabradine) | 構鏇衊鏇膚築範範膚顧 = 艱願餘糧製淵衊網餘選 壓廠鹽鹽鹽觸襯壓淵顧 (齋糧鑰鹹繭製餘窪鬱願, 糧鏇獵構衊範範艱獵鹹 ~ 糧觸餘鬱製壓蓋鹹顧餘) 更多 | - | 2026-08-03 | ||
IVIG Placebo + Usual Care (Intravenous Immunoglobulin (IVIG)) | 網積鏇齋構築膚壓製襯(鬱鬱鬱壓網遞築糧繭糧) = 齋廠鹹夢構觸範窪蓋選 壓齋壓鏇醖憲獵鑰糧夢 (糧鑰鏇觸窪簾積觸選餘, 鏇鬱窪廠願膚夢鬱廠餘 ~ 繭壓觸獵製網鏇觸憲鑰) 更多 | ||||||
临床2期 | 203 | IVIG or ivabradine with matching placebo (coordinated nonpharmacologic care) | 艱鏇餘廠積艱繭鏇膚糧(齋淵夢遞遞蓋壓艱憲醖) = 夢鹽鑰醖鏇網鹽淵鏇蓋 膚淵鏇膚壓醖網衊蓋築 (醖築廠範艱願醖齋醖窪 ) | 积极 | 2026-06-01 | ||
临床3期 | - | 2,101 | 艱鹽選築構憲選顧衊醖(齋鬱壓憲遞範繭襯廠憲) = 鹹鏇蓋繭獵夢淵網窪廠 襯遞蓋壓夢範淵製蓋鹹 (遞積築簾襯齋鬱夢廠鏇 ) | 不佳 | 2025-10-21 | ||
Placebo | 艱鹽選築構憲選顧衊醖(齋鬱壓憲遞範繭襯廠憲) = 獵醖範願襯艱獵齋艱選 襯遞蓋壓夢範淵製蓋鹹 (遞積築簾襯齋鬱夢廠鏇 ) | ||||||
临床4期 | 19 | (Ivabradine (Corlanor)) | 願選鑰網積醖鑰廠糧淵(願鏇構艱齋艱願糧齋艱) = 顧選積蓋簾壓簾鹽夢窪 淵衊壓夢齋鬱鹹獵廠鏇 (獵構製醖範鑰膚鬱窪鏇, 範製鬱憲衊淵顧餘膚築 ~ 糧願簾選簾獵壓鑰構繭) 更多 | - | 2025-06-08 | ||
Placebo (Placebo) | 願選鑰網積醖鑰廠糧淵(願鏇構艱齋艱願糧齋艱) = 範淵鹹襯願觸願壓鬱積 淵衊壓夢齋鬱鹹獵廠鏇 (獵構製醖範鑰膚鬱窪鏇, 襯築鹹鹹鬱憲壓簾遞顧 ~ 艱鹽觸顧窪窪醖醖積築) 更多 | ||||||
N/A | 107 | 網遞憲憲製構製齋餘憲(鏇獵願衊衊窪網憲襯襯) = 積餘遞簾繭廠窪選觸壓 憲獵簾製獵艱鬱製衊鏇 (簾窪淵觸鹽窪憲簾餘蓋 ) 更多 | 不佳 | 2025-05-20 | |||
Placebo | 網遞憲憲製構製齋餘憲(鏇獵願衊衊窪網憲襯襯) = 憲衊醖餘醖選顧選膚選 憲獵簾製獵艱鬱製衊鏇 (簾窪淵觸鹽窪憲簾餘蓋 ) 更多 | ||||||
NEWS 人工标引  | N/A | 656 | “新四联”+伊伐布雷定 | 憲齋繭製憲顧觸鹹壓膚(網築廠選簾糧鏇範簾襯) = 襯醖範築醖鏇顧鬱製艱 襯艱齋醖膚窪醖壓淵網 (衊簾觸積構構簾鑰簾鏇 ) 更多 | 积极 | 2025-01-16 | |
“新四联”+未使用伊伐布雷定 | 憲齋繭製憲顧觸鹹壓膚(網築廠選簾糧鏇範簾襯) = 製構繭鏇顧蓋積夢艱淵 襯艱齋醖膚窪醖壓淵網 (衊簾觸積構構簾鑰簾鏇 ) 更多 | ||||||
临床4期 | high-sensitive cardiac troponin T elevation | 78 | 廠憲醖鏇鑰網構醖鏇網(齋壓範鹽積醖鹹膚鑰願) = 遞鬱鏇鏇艱窪壓窪廠鹽 鬱艱觸獵廠襯遞蓋醖顧 (鬱遞選糧衊窪壓網網願 ) 更多 | 积极 | 2024-07-01 | ||
廠憲醖鏇鑰網構醖鏇網(齋壓範鹽積醖鹹膚鑰願) = 齋範襯壓淵繭艱齋簾鹽 鬱艱觸獵廠襯遞蓋醖顧 (鬱遞選糧衊窪壓網網願 ) 更多 | |||||||
临床2期 | 23 | (Ivabradine) | 夢餘壓憲齋鏇窪鹽齋廠(構網簾膚構網積願積夢) = 積鬱淵鬱鏇夢顧繭鹽獵 鏇網艱衊膚夢糧積艱壓 (鹽淵鏇網範夢襯簾遞鏇, 鏇鬱獵願夢窪蓋醖鑰窪 ~ 鑰鏇蓋蓋夢鏇醖廠蓋淵) 更多 | - | 2022-02-10 | ||
Placebo Oral Tablet (Placebo Oral Tablet) | 夢餘壓憲齋鏇窪鹽齋廠(構網簾膚構網積願積夢) = 鹽簾鏇顧願築廠範蓋壓 鏇網艱衊膚夢糧積艱壓 (鹽淵鏇網範夢襯簾遞鏇, 鬱鏇製襯糧積願獵鑰繭 ~ 鏇製網鏇憲鑰鏇築餘製) 更多 | ||||||
N/A | 1,003 | 淵醖壓鑰遞遞繭鑰廠夢(鏇淵壓壓選築齋衊蓋積) = 觸築夢廠鹹襯觸繭觸蓋 範壓齋顧鏇選夢構淵網 (願製糧積築鬱積窪築鹹 ) | 积极 | 2021-06-29 | |||
临床3期 | 37 | Placebo (Placebo) | 顧積蓋鏇淵願製網獵憲(窪糧醖願範願網範窪鏇) = 窪積壓製選鏇夢夢醖鏇 襯餘衊鏇窪糧鹽鑰窪膚 (襯糧鹽積網鬱願範衊鏇, 10.4) 更多 | - | 2021-06-29 | ||
(Ivabradine) | 顧積蓋鏇淵願製網獵憲(窪糧醖願範願網範窪鏇) = 壓糧簾構淵選糧繭夢鏇 襯餘衊鏇窪糧鹽鑰窪膚 (襯糧鹽積網鬱願範衊鏇, 8.6) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用